title: Vasa praevia: risk-adapted modification of the conventional management--a retrospective study.
abstract: OBJECTIVE
  Undiagnosed vasa praevia carries an imminent risk of fetal death and increases with IVF. When diagnosed, the question arises as to whether the conventional prenatal management of routine steroid administration for fetal lung maturation and elective caesarean section in week 35 is generally justified in face of the risks involved. We present a retrospective study of a risk-adapted modification of the conventional management of vasa praevia.
  
  
  METHODS
  We analysed 11 years of records involving 18 cases of antenatally diagnosed vasa praevia at our perinatal centre. Each case was managed by a risk-adapted modification of the conventional treatment where both, the steroid administration and the timing of delivery, were dependent on the patient history and clinical signs for preterm birth.
  
  
  RESULTS
  There were no lethal fetal, neonatal, or maternal complications. The earliest caesarean section took place at 34 weeks 1 day, the latest at 37 weeks 1 day, and in more than half of the cases at ≥ 36 weeks.
  
  
  CONCLUSIONS
  Steroid application is generally recommended for pregnancies before 34 weeks carrying a risk for preterm birth. Thus, retrospectively, none of our cases required steroid administration. This supports our protocol of not obligatorily administering steroids. Delaying the caesarean section up to two weeks beyond the conventionally recommended date of 35 weeks in 78% of our cases resulted in no complications. This justifies the suitability of determining the timing of delivery based on our individual patient assessment. In conclusion, the following recommendations for a risk-adapted management of vasa praevia can be made: 1. weekly evaluation of risk factors for preterm delivery; 2. steroid administration only at risk for preterm birth; 3. admission to hospital with full obstetric and neonatal care facilities between 32 and 34 weeks; 4. elective caesarean section between 35 and 37 weeks, risk-adapted.
authors.affiliation: Klinik für Geburtsmedizin, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Germany. michaela.golic@charite.de
authors.forename: M
authors.initials: M
authors.lastname: Golic
authors.forename: L
authors.initials: L
authors.lastname: Hinkson
authors.forename: C
authors.initials: C
authors.lastname: Bamberg
authors.forename: E
authors.initials: E
authors.lastname: Rodekamp
authors.forename: M
authors.initials: M
authors.lastname: Brauer
authors.forename: N
authors.initials: N
authors.lastname: Sarioglu
authors.forename: W
authors.initials: W
authors.lastname: Henrich
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D002585:Cesarean Section; D003937:Diagnosis, Differential; D005260:Female; D005313:Fetal Death; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D010920:Placenta / Q000098:blood supply / Q000000981:diagnostic imaging / Q000473:pathology; D011247:Pregnancy; D011256:Pregnancy Outcome; D012189:Retrospective Studies; D012422:Rupture, Spontaneous; D018615:Ultrasonography, Doppler, Color; D016216:Ultrasonography, Prenatal; D055949:Vasa Previa / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy*
chemical_list: D000305:Adrenal Cortex Hormones